Monday, November 8, 2010 (Last Updated: 11/09/2010)
MONDAY, Nov. 8 (HealthDay News) -- Important recent advances in cancer research include studies assessing improved drug therapies, methods for reducing the risk of disease recurrence, and treatments for improving progression-free survival, according to a new report from the American Society of Clinical Oncology published online Nov. 8 in the Journal of Clinical Oncology.
In "Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology," the authors cover major and notable cancer-related advances from the past year. The report touches on the use of FOLFIRINOX -- a combination of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin -- in advanced pancreatic cancer; the use of hypofractionated radiation therapy for preventing recurrence in early-stage breast cancer; and improving progression-free survival in ovarian cancer with chemotherapy and bevacizumab.
In addition, the authors urge the doubling of funds for the National Cancer Institute's Cooperative Group trials program during the next five years, and call for implementation of the recommendations in the Institute of Medicine's recent "A National Cancer Clinical Trials System for the 21st Century" report.
"This year's Annual Report on Progress Against Cancer highlights those studies that have had the greatest impact on patient care," Mark G. Kris, M.D., the report's executive editor, said in a statement. "Yet much work is still needed to advance clinical cancer research and care. We're on the verge of great discoveries, but we will not be able to speed the pace of progress without revitalizing the nation's clinical trial system."
Hematology & Oncology
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.